1. General information about cookies:

A cookie is a small text file that is placed on the user’s terminal (PC, smartphone, tablet or other device) when they access the website. Cookies store and retrieve information about browsing on this terminal. They are not harmful and do not damage the terminal.



2. Cookies on this website:

The use of cookies means, for example, that we can provide a better browsing experience to our users. They help us to identify the user (if they are registered), remember their browsing preferences, conduct studies on usage patterns to improve our website, identify profiles to send personalized advertising, etc.

Below is a list of the type of cookies used and their description:

• First-party cookies: they are sent to the user’s terminal from a computer or domain, managed by the publisher and used to provide the requested service to the user.

• Third-party cookies: they are sent to the user’s terminal from a computer or domain which is not managed by the publisher but rather by another organization that processes the data obtained via the cookies. The table below contains a list of the third-party cookies which we use on this website.

• Session cookies: they are cookies designed to gather and store data while the user is on a website. • Persistent cookies: they are cookies in which the data are stored on the terminal and can be accessed and processed for a time specified by the controller which may range from a few minutes to several years.

• Analysis cookies: these are cookies processed by us or by third parties which enable us to quantify the number of users and thus measure and statistically analyse how users are using the service we provide. This involves analysing their browsing on our website in order to enhance our products or services.

• Advertising cookies: these cookies make it possible to efficiently manage advertising that the publisher has included on a website, app or platform which is used to deliver the requested service based on criteria such as content published or the frequency with which the ads are displayed.



Below is a list of the main cookies used by GRUPO FERRER INTERNACIONAL, SA: (include as relevant).



Service/Cookie name

Provider name [they may be first-party or third-party]

Purpose/More information [explain the purpose or give a link which redirects to the privacy policy of the cookie provider]

7c895bed0e6f4ab589585e56ba0ea5

noventure.com

Session

_ga

.noventure.com

 

_gat

.noventure.com

 



It is also possible that when visiting a website or opening an email where an ad or promotion for our products or services is published, a cookie is installed on the user’s browser that we use to monitor our ads in terms of, for example, the number of times they are viewed, where they appear, at what time they are viewed, etc.

It may be that some cookies used on this website are unrelated to GRUPO FERRER INTERNACIONAL, SA. This is because some pages on the website contain content from third-party websites. Because this content comes from another website, GRUPO FERRER INTERNACIONAL, SA does not control the settings of these cookies. If you wish to change your cookie setting preferences, you should see the websites of these third parties for more information.



3. Third-party service providers:

In particular, the parties from which we have hired a service in which the use of cookies is required are:



Service/Cookie name

Provider name

Purpose/More information





4. Managing cookies: disabling and deleting:

Users can configure their browser to be notified of the receipt of cookies and to prevent their installation on their computer. However, disabling cookies may affect the operation of the website. Please consult the instructions and manuals of your browser for more information.

In addition and depending on the browser used, the user can activate any of the following options to limit the scope of the cookies installed or their operation:

- private browsing, whereby your browser stops saving your browsing history, website passwords, cookies and other information from the pages you visit, or

- do not track function, by which the browser asks the websites you visit not to track your browsing habits in order to, for example, serve advertising matched to your interests on the sites you visit.

It may be that some cookies used on this website are unrelated to GRUPO FERRER INTERNACIONAL, SA. This is because some pages on the website contain content from third-party websites (such as for example a YouTube video). Because this content comes from another website, GRUPO FERRER INTERNACIONAL, SA does not control the settings of these cookies. If you wish to change your cookie setting preferences, you should see the websites of these third parties for more information.

If you want more control over the installation of cookies, you can install programs or add-ons on your browser known as “Do Not Track” tools which enable you to choose the cookies you want to allow.

Finally, please note that you can at any time withdraw your consent to the use of cookies by GRUPO FERRER INTERNACIONAL, SA by configuring your browser in way specified in the previous section.

Tasectan ®

PUBLICATION

 

MAGAZINE/CONGRESS

     
Allegrini A. & Constantini M., “Gelatine Tannate for the treatment of Acute Diarrhoea in Adults”   J Gastroint Dig Syst 2012, 2:3.
     
Guzganu I., “Severe Diarrhea in a 4-month-old baby girl with acute gastroenteritis: a case report and review of the literature”

 

Case Reports in Gastrointestinal Medicine, Volume 2012.
     
Allegrini A. et al. “Tasectan (gelatine tannate) for the treatment of acute gastroenteritis in children: Preliminary results from a study conducted to evaluate its efficacy and safety”   Poster published at the 39th annual paediatric Belgium society congress, Brussels, March 2011
     
Carretero et al, “A comparative analysis of response to ORS (oral rehydration solution) vs. ORS + gelatine tannate in two cohorts of paediatric patients with acute diarrhoea”

 

Rev. Esp. Enferm. Dig, Vol.101 Nº1, pp. 41-48, 2009.
     
Durban Reguera F. et al, “Prospective Observational Study on Infants and children with Acute Diarrhoea treated with gelatine tannate”.

 

Poster Published at “Semana de las Enfermedades Digestivas” in Madrid (Spain), June 2007.
     
Durban Reguera F. et al, “Prospective Observational Study on Adults with Acute Diarrhoea treated with gelatine tannate”.

 

Poster Published at “Semana de las Enfermedades Digestivas” in Madrid (Spain), June 2007.
     

Freli V. et al, "New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 1: film-forming effect".

 

Presented as oral communication at the 33rd edition of the Congress from the Groupe Francophone d'Hépato-Gastroentérologie et Nutrition Pédiatriques in Nantes, France, on 30th March 2012.
     
De Servi B, et al., “New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 2: antibacterial activity”.

 

Presented as oral communication at the 33rd edition of the Congress from the Groupe Francophone d'Hépato-Gastroentérologie et Nutrition Pédiatriques in Nantes, France, on 30th March 2012.
     
L. Bueno et al, “Undissociated Gelatine Tannate reduces intestinal leakiness and mucosa inflammation by forming a protective biofilm: results from in- vitro and in-vivo studies”

 

UEG Journal - United European Gastroenterology Journal, Oct.2013: Vol. 1, Supl. 1; ISSN 2050-6406 (print) ISSN 2050-6414 (online).
     

XilaPlus®

PUBLICATION

 

MAGAZINE/CONGRESS

     
Lucio Gnessi, Vladimir Bacarea, Marius Marusteri and Núria Piqué. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.   BMC Gastroenterology (2015) 15:153
     
Lucio Gnessi, Xavier Llop, Núria Piqué. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.

 

23rd UEG WEEK BARCELONA. October 24-28 2015
     
Catalin Pleasea Condratovici, Vladimir C. Bacârea, Núria Piqué. Xyloglucan for the treatment of acute gastroenteritis in children: results of a randomized, controlled, clinical trial.

 

Gastroenterology Research and Practice. April 2016
     
Catalin Pleasea Condratovici, Xavier Llop, Núria Piqué, Vladimir Bacarea. Xyloglucan for the treatment of acute gastroenteritis in children: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.   23rd UEG WEEK BARCELONA. October 24-28 2015
     

Utipro Plus®

PUBLICATION

 

MAGAZINE/CONGRESS

     
Alejandro García-Larrosa and Octavian Alexe. Efficacy and Safety of a Medical Device versus Placebo in the Early Treatment of Patients with Symptoms of Urinary Tract Infection: A Randomized Controlled Trial.   Clin Microbiol 2016, 5:1
     
Nicola Salvatorelli, Alejandro García-Larrosa, Alessandro Allegrini, Daniele Pavone. A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial.   Urol Int. Published online: April 8, 2016
     
Barbara de Servi1, Francesco Ranzini1 & Nuria Piqué*. Effect of Utipro® (containing gelatin- xyloglucan) against Escherichia coli invasion of intestinal epithelial cells: results of an in vitro study.

 

Future Microbiology. Posted online on March 29, 2016.
     
Hélène Eutamene, Cherryl Harkat, Valérie Bezirard, Vassilia Theodorou. Undissociated gelatin tannate and xyloglucan prevent gut leakiness and mucosal inflammation induced by LPS: Insights in the Mechanism of action.

 

UEG Week. Vienna October 2016.
     
Maïwenn Olier, Soraya Sekkal, Cherryl Harkat, Hélène Eutamène, Vassilia Theodorou, Lionel Bueno. In vivo evaluation of properties of a new medical device against intestinal commensals with uropathogenic potential   American Gastroenterology association congress (May 2016)
     
Alex García-Larrosa. Utipro® un nuevo tratamiento efectivo contra los síntomas de cisititis aguda.

 

Spanish national Urology Congress. Tenerife 2014.
     
Alex García-Larrosa, Xavier Llop. Utipro® is more effective than placebo in reducing recurrent cystitis. Preliminary results.

 

XXI Congresso nazionale AURO II. Roma 2014
     

Gelsectan®

PUBLICATION

 

MAGAZINE/CONGRESS

     
Octavian Alexea, Vlad Bacarea and Nuria Pique. The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial.   United European Gastroenterology Journal. June 2016 vol. no. 3 455-465

http://ueg.sagepub.com/content/4/3/455.full.pdf
     
       
This area contains information intended exclusively for health professionals authorized to prescribe or dispense pharmaceutical products.
   
Calle Consejo de Ciento, 333
08007 Barcelona, Spain

Contact us

info@noventure.com
NOVENTURE S.L.
Tel: +34.93.205.27.18